Citius Pharmaceuticals is trading 10.33% up at $0.50 on October 27, 2026, after preliminary fourth-quarter LYMPHIR shipments to U.S. wholesalers rose 120%. - Citius Oncology reported the preliminary, unaudited increase on October 26: 792 units, versus 360 in the prior quarter. - The update also cited 950 institutional vial orders and 54 institutions ordering LYMPHIR. - Shares rose 11.38% on October 26; broader market strength may also support sentiment, though the shipment update is the clearest company-specific news.